CYTK - サイトキネティクス （Cytokinetics Incorporated） サイトキネティクスCYTKのチャート
CYTKの企業情報
| symbol | CYTK |
|---|---|
| 会社名 | Cytokinetics Inc （サイトキネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サイトカイネティックス(Cytokinetics Incorporated)は後期バイオ医薬品会社である。同社は筋肉のパフォーマンスが損害あるいは低下などの衰弱性疾患の潜在的治療法としてのファースト・イン・クラス筋肉活性化因子の発見、開発、商業化などを行う。重病治療のために筋肉機能を調節する小分子治療法の発見と開発を中心とする。同社の臨床階段の薬品候補はtirasemtiv、CK-2127107とomecamtiv mecarbilを含む。同社は筋萎縮性側索硬化症（ALS）の治療のためのティラセミチブ薬候補を開発する。脊髄性筋萎縮、慢性閉塞性肺疾患およびALSの潜在的治療薬としてCK-2127107を開発する。Omecamtiv mecarbilは心不全の治療するための心筋ミオシンアクチベーターである。 サイトキネティクスは、米国の医薬品会社。心不全治療を適応とする医薬品薬候補の発見、開発、商業化に従事。主に、筋萎縮性側索硬化症に対する｢Tirasemtiv(正式名称：CK-2017357)｣の臨床試験に焦点を当てている。本社はカリフォルニア州サウスサンフランシスコ。 Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. |
| 本社所在地 | 280 East Grand Avenue South San Francisco CA 94080 USA |
| 代表者氏名 | Leonard Patrick Gage レナード・パトリック・ゲージ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-624-3000 |
| 設立年月日 | 35643 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 137人 |
| url | www.cytokinetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -112.14400 |
| 終値（lastsale） | 8.23 |
| 時価総額（marketcap） | 449588415.31 |
| 時価総額 | 時価総額（百万ドル） 429.92230 |
| 売上高 | 売上高（百万ドル） 17.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 230.34630 |
| 当期純利益 | 当期純利益（百万ドル） -130.64600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytokinetics Inc. revenues increased 59% to $11.5M. Net loss increased 5% to $57.8M. Revenues reflect Revenue Sales of Goods_Serv increase from $818K to $8.3M. Higher net loss reflects Research and development increase of 12% to $43.7M (expense) Non-cash interest expense on liability r increase of 41% to $8.5M (expense) General and administrative increase of 5% to $17.3M (expense). |
CYTKのテクニカル分析
CYTKのニュース
Cytokinetics Incorporated (NASDAQ: CYTK)’s Stock Is Down -2.83% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 2022/12/09 19:00:00 Marketing Sentinel
During the recent session, Cytokinetics Incorporated (NASDAQ:CYTK)’s traded shares were 0.92 million, with the beta value of the company hitting 1.00. At the last check today, the stock’s price was $37.62, reflecting an intraday gain of 4.50% or $1.62. The 52-week high for the CYTK share is $55.80, that puts it down -48.33 from that … Cytokinetics Incorporated (NASDAQ: CYTK)’s Stock Is Down -2.83% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics'' potential heart drug 2022/12/09 18:56:08 Endpoints News
The FDA''s Cardiovascular and Renal Drugs Advisory Committee will meet next Tuesday to discuss whether Cytokinetics'' potential heart drug can safely reduce the risk of cardiovascular death and heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction. The drug, known as omecamtiv mecarbil and in development
FDA staff reviewers flag safety concerns over Cytokinetics’ heart drug 2022/12/09 17:47:34 Financial Post
U.S. Food and Drug Administration staff reviewers on Friday identified safety and efficacy concerns about Cytokinetics Inc’s heart drug, according to briefing documents published on the agency’s website. The late-stage data raises concerns about the drug’s dose-limiting risks of heart failure, the reviewers said, adding it is unclear if the study would be enough to […]
CYTK stock dips as FDA posts briefing documents on heart failure therapy (NASDAQ:CYTK) 2022/12/09 14:29:55 Seeking Alpha
Shares of the clinical-stage biotech Cytokinetics (CYTK) fell in the pre-market trading Friday after the FDA briefing documents ahead of an advisory committee meeting scheduled next week…
Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil 2022/12/09 13:59:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).
Hot Stocks: IRBT jumps on AMZN merger deal; CYTK rallies; WBD, HYZN drop 2022/08/05 21:52:39 Seeking Alpha
IRBT jumped on a merger deal with AMZN. CYTK climbed after its quarterly update. WBD dropped on its earnings news. HYZN plunged.
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M 2022/08/05 12:16:40 Benzinga
Cytokinetics Inc (NASDAQ: CYTK ) reported Q2 sales of $88.96 million compared to $2.84 million a year ago, primarily due to the recognition of $87 million deferred revenue for sales royalties of mavacamten as a result of the extinguishment of royalty obligations. The analysts estimated sales of $3.63 million. The company reported an EPS loss of $(0.23), down from $(0.86) a year … Full story available on Benzinga.com
Cytokinetics PT Raised to $53 at JMP Securities 2022/08/05 07:33:02 Investing.com
https://www.investing.com/news/pro/cytokinetics-pt-raised-to-53-at-jmp-securities-432SI-2864530
Recap: Cytokinetics Q2 Earnings 2022/08/04 21:31:29 Benzinga
Cytokinetics (NASDAQ: CYTK ) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Cytokinetics beat estimated earnings by 77.45%, reporting an EPS of $-0.23 versus an … Full story available on Benzinga.com
Cytokinetics GAAP EPS of -$0.23 beats by $0.81, revenue of $88.97M beats by $85.24M (NASDAQ:CYTK) 2022/08/04 20:13:15 Seeking Alpha
Cytokinetics press release (CYTK): Q2 GAAP EPS of -$0.23 beats by $0.81.Revenue of $88.97M (+3032.7% Y/Y) beats by $85.24M.Revised 2022 Financial Guidance: The company today revised…
Cytokinetics Incorporated (NASDAQ:CYTK) Stock Dropped -13.80% Year-To-Date, What Analysts Expect Next? 2022/07/01 11:00:00 Marketing Sentinel
In last trading session, Cytokinetics Incorporated (NASDAQ:CYTK) saw 10.35 million shares changing hands with its beta currently measuring 1.05. Company’s recent per share price level of $39.29 trading at -$9.45 or -19.39% at ring of the bell on the day assigns it a market valuation of $3.38B. That closing price of CYTK’s stock is at … Cytokinetics Incorporated (NASDAQ:CYTK) Stock Dropped -13.80% Year-To-Date, What Analysts Expect Next? Read More »
Cytokinetics prices $450M of convertible debt offering 2022/07/01 08:00:27 Seeking Alpha
Cytokinetics, Incorporated (CYTK) has priced its offering of $450.0M aggregate principal amount of 3.50% convertible senior notes due 2027
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering 2022/07/01 07:35:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).